Information Provided By:
Fly News Breaks for August 20, 2019
Aug 20, 2019 | 12:02 EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $230 price target on Vertex Pharmaceuticals, after the FDA accepted the New Drug Application, or NDA, for Vertex's TripleRx VX-445 + SYMDEKO, setting a March 19 PDUFA date. Tenthoff said he is "confident in approval" based on "unprecedented efficacy in Phase III trials."
News For VRTX From the Last 2 Days
There are no results for your query VRTX